Oligodendroglioma Overview

Save information for later
Sign Up

Learn About Oligodendroglioma

View Main Condition: Brain Tumor

What is the definition of Oligodendroglioma?
Oligodendroglioma is a type of brain tumor that develops from oligodendrocytes, which are specialized cells that protect neurons (nerve cells). Oligodendroglioma can occur in the brain and spinal cord.  Oligodendrogliomas are also classified as either Grade 2 or Grade 3. Grade 2 oligodendrogliomas do not spread as aggressively as Grade 3 and are less likely to cause severe symptoms. 
What are the causes of Oligodendroglioma?
The cause of oligodendrogliomas is still unknown. However, oligodendrogliomas generally tend to be more common in adults than children. Men are also more likely to develop oligodendrogliomas than women.
What are the symptoms of Oligodendroglioma?
Symptoms for oligodendroglioma primarily depend on the size and location of the tumor. Common symptoms include seizures, headaches, short-term memory issues, personality changes, and weakness on one side of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Oligodendroglioma?
Treatment for oligodendroglioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove the tumor is generally the first step in treating oligodendroglioma. Depending on the tumor's location, surgery may be able to entirely remove smaller oligodendrogliomas. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of oligodendrogliomas. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Oligodendroglioma Local Doctors?
Katherine B. Peters
Elite in Oligodendroglioma
Dr. Katherine B. Peters
Neurology
Elite in Oligodendroglioma
Dr. Katherine B. Peters
Neurology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Katherine Peters is a Neurologist in Durham, North Carolina. Dr. Peters is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Glioma, Gliomatosis Cerebri, Brain Tumor, and Astrocytoma. Dr. Peters is currently accepting new patients.

Elite in Oligodendroglioma
Dr. John F. De Groot
Neurology
Elite in Oligodendroglioma
Dr. John F. De Groot
Neurology

Ucsf Medical Group Business Services

521 Parnassus Ave, 
San Francisco, CA 
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John De Groot is a Neurologist in San Francisco, California. Dr. De Groot is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Oligodendroglioma
Dr. Marta Penas-Prado
Neurology
Elite in Oligodendroglioma
Dr. Marta Penas-Prado
Neurology
1515 Holcombe Blvd, 
Houston, TX 
713-792-6161
Languages Spoken:
English

Marta Penas-Prado is a Neurologist in Houston, Texas. Dr. Penas-Prado is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. Her top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, and Glioma.

View All Doctors
What is the outlook (prognosis) for Oligodendroglioma?
The prognosis for oligodendroglioma is very good with current treatments. When the tumor can be removed, survival rates are over 90%. If the tumor can not be removed but radiation therapy is used, survival rates are between 80-90%.
How do I prevent Oligodendroglioma?
There is no known way to prevent oligodendrogliomas. However, if you develop any symptoms common to oligodendroglioma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Oligodendroglioma Clinical Trials?
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Who is this study for: Patients with recurrent and rare primary central nervous system neoplasms
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: ONC206
Study Phase: Phase 1

Summary: The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) ne...

Match to trials
Find the right clinical trials for you in under a minute
Get started
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
Enrollment Status: Recruiting
Publish Date: December 10, 2025
Intervention Type: Biological, Drug
Study Phase: Phase 1

Summary: This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.